Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Occupational Rehabilitation
Published in: Journal of Occupational Rehabilitation 4/2015

01-12-2015

Validation of the Chinese Version of the Cognitive Symptom Checklist-Work-21 in Breast Cancer Survivors

Authors: Andy S. K. Cheng, Yingchun Zeng, Michael Feuerstein

Published in: Journal of Occupational Rehabilitation | Issue 4/2015

Login to get access

Abstract

Purpose The purpose of this study was to translate the Cognitive Symptom Checklist-Work-21 (CSC-W21), into Chinese, and culturally adapt and validate the Chinese version, a measure of work-related cognitive limitations in occupationally active breast cancer survivors (BCS). Methods The translation of the English version of the CSC-W21 followed a systematic procedure. Exploratory factor analysis was used to identify factor structures. The internal consistency of the factors was assessed by calculating the Cronbach’s alpha reliability coefficients. Item- and scale-level content validity was determined. The intra-class correlation coefficient (ICC) was used to analyze test–retest reliability. A total of two hundred and twenty BCS participated in the psychometric testing of the CSC-W21-C. The construct validity of the total score of the CSC-W21-C was determined through convergent validity and an analysis of its relationship with the four subscales of the Work Limitations Questionnaire (WLQ), a measure of four types of job task difficulties. Results The CSC-W21-C demonstrated item- and scale-level content validity (>.80). The factor structure of the CSC-W21-C was similar to the original English version. The internal consistency of the subscales of the CSC-W21-C ranged from .84 to .95. The ICC was between .80 and .96 indicating good test–retest reliability. The CSC-W21-C was significantly correlated with the WLQ, particularly the mental-interpersonal subscale, where it accounted for 27.3 % of the total variance. Conclusions The findings indicate that the CSC-W21-C has sound measurement properties that strongly suggest it can be used in future assessment and intervention research to identify cognitive limitations related to specific work tasks in BCS.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Fantoni SQ, Peugniez C, Duhamel A, Skrzypczak J, Frimat P, Leroyer A. Factors related to return to work by women with breast cancer in Northern France. J Occup Rehabil. 2010;20:49–58.CrossRefPubMed
3.
Linos E, Spanos D, Rosner BA, Linos K, Hesketh T, Qu JD, et al. Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. J Natl Cancer Inst. 2008;100(19):1352–60.PubMedCentralCrossRefPubMed
4.
China National Cancer Institute. 2012 Annual Oncology Report. Ministry of Health, Bureau of Disease Prevention, Beijing.
5.
Roelen CA, Koopmans PC, van Rhenen W, Groothoff JW, van der Klink JJ, Bültmann U. Trends in return to work of breast cancer survivors. Breast Cancer Res Treat. 2011;128(1):237–42.CrossRefPubMed
6.
7.
Liu S, Zhao J, Liu J, Sun ZP, Hua YQ, Lu DM, et al. Effects of mastectomy on the 5-year recurrence rate in breast cancer patients. J Chin Integr Med. 2008;6(10):1000–4 [in Chinese].CrossRef
8.
Bouknight RR, Bradley CJ, Luo Z. Correlates of return to work for breast cancer survivors. J Clin Oncol. 2006;24:345–53.CrossRefPubMed
9.
Quesnel C, Savard J, Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat. 2009;116(1):113–23.CrossRefPubMed
10.
Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat. 2008;110(1):143–52.PubMedCentralCrossRefPubMed
11.
Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76–89.CrossRefPubMed
12.
Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005;59:60–70.CrossRefPubMed
13.
Von Ah D, Harvison KW, Monahan PO, Moser LR, Zhao Q, Carpenter JS, et al. Cognitive function in breast cancer survivors compared to healthy age- and education-matched women. Clin Neuropsychol. 2009;23(4):661–74.CrossRef
14.
Fan HG, Houédé-Tchen N, Yi QL, Chemerynsky I, Downie FP, Sabate K, Tannock IF. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2- year follow-up of a prospective controlled study. J Clin Oncol. 2005;23(31):8025–32.CrossRefPubMed
15.
Bender CM, Pacella ML, Sereika SM, Brufsky AM, Vogel VG, Rastogi P, et al. What do perceived cognitive problems reflect? J Support Oncol. 2008;6(5):238–42.PubMedCentralPubMed
16.
Palmer J, Trotter T, Joy A, Carlson L. Cognitive effects of tamoxifen in pre-menopausal women with breast cancer compared to healthy controls. J Cancer Surviv. 2008;2(4):275–82.CrossRefPubMed
17.
Eberling J, Wu C, Tong-Turnbeaugh R, Jagust W. Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage. 2004;21(1):364–71.CrossRefPubMed
18.
Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld LD. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007;11(26):iii–iv, ix–xi, 1–134.
19.
Bender CM, Sereika SM, Brufsky AM, Ryan CM, Vogel VG, Rastogi P, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause. 2007;14(6):995–8.PubMedCentralCrossRefPubMed
20.
Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100:2292–9.CrossRefPubMed
21.
22.
Deimling GT, Bowman KF, Sterns S, Wagner LJ, Kahana B. Cancer-related health worries and psychological distress among older adult, long-term cancer survivors. Psychooncology. 2006;15:306–20.CrossRefPubMed
23.
Gandubert C, Carrière I, Escot C, Soulier M, Hermès A, Boulet P, et al. Onset and relapse of psychiatric disorders following early breast cancer: a case–control study. Psychooncology. 2009;18:1029–37.CrossRefPubMed
24.
Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology. 2004;13(1):61–6.CrossRefPubMed
25.
Hansen JA, Feuerstein M, Calvio LC, Olsen CH. Breast cancer survivors at work. J Occup Environ Med. 2008;50(7):777–84.CrossRefPubMed
26.
27.
Mehnert A. Employment and work related issues in cancer survivors. Crit Rev Oncol Hematol. 2011;77:109–30.CrossRefPubMed
28.
Amir Z, Neary D, Luker K. Cancer survivors’ views of work 3 years post diagnosis: a UK perspective. Eur J Oncol Nurs. 2008;12:190–7.CrossRefPubMed
29.
Balak F, Roelen CA, Koopmans PC, ten Berge EE, Groothoff JW. Return to work after early-stage breast cancer: a cohort study into the effects of treatment and cancer-related symptoms. J Occup Rehabil. 2008;18:267–72.CrossRefPubMed
30.
Pryce J. Cancer survivorship and work: symptoms, supervisor response, co-worker disclosure and work adjustment. J Occup Rehabil. 2007;17(1):83–92.CrossRefPubMed
31.
Spelten E, Verbeek J, Uitterhoeve AL, Ansink AC, van der Lelie J, de Reijke TM, et al. Cancer, fatigue and the return of patients to work—a prospective cohort study. Eur J Cancer. 2003;39:1562–7.CrossRefPubMed
32.
Wagner L, Sweet J, Butt Z, Lai J, Cella D. Measuring patient self reported cognitive function: development of the Functional Assessment of Cancer Therapy-Cognitive Function Instrument. J Support Oncol. 2009;7:W32–9.
33.
Breckenridge LM, Bruns GL, Todd BL, Feuerstein M. Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors. Psychooncology. 2012;21(1):43–53.CrossRefPubMed
34.
Ottati A, Feuerstein M. Brief self-report measure of work-related cognitive limitations in breast cancer survivors. J Cancer Surviv. 2013;7:262–73.CrossRefPubMed
35.
Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol. 1993;46(12):1417–32.CrossRefPubMed
36.
Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine. 2000;25(24):3186–91.CrossRefPubMed
37.
Polit DF, Beck CT, Owen SV. Is the CVI an acceptable indicator of content validity? Appraisal and recommendations. Res Nurs Health. 2007;30:459–67.CrossRefPubMed
38.
Portney LG, Watkins MP. Foundations of Clinical Research: Application to Practice. 3rd ed. London: Prentice-Hall; 2009.
39.
Calvio L, Peugeot M, Bruns GL, Todd BL, Feuerstein M. Measures of cognitive function and work in occupationally active breast cancer survivors. J Occup Environ Med. 2010;52(2):219–27.CrossRefPubMed
40.
Feuerstein M, Hansen JA, Calvio LC, Johnson L, Ronquillo JG. Work productivity in brain tumor survivors. J Occup Environ Med. 2007;49:803–11.CrossRefPubMed
41.
Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance Systems Survey Questionnaire: US Department of Health and Human Services. Atlanta, GA: Centers for Disease Control and Prevention; 1999.
42.
Lerner D, Amick BC III, Rogers WH, Malspeis S, Bungay K, Cynn D. The Work Limitations Questionnaire. Med Care. 2001;39:72–85.CrossRefPubMed
43.
Tamminga SJ, Verbeek J, Frings-Dresen M, Boer A. Measurement properties of the Work Limitations Questionnaire were sufficient among cancer survivors. Qual Life Res. 2014;23:515–25.CrossRefPubMed
44.
45.
Katz MR, Kopek N, Waldron J, Devins GM, Tomlinson G. Screening for depression in head and neck cancer. Psychooncology. 2004;13:269–80.CrossRefPubMed
46.
Alexander S, Palmer C, Stone PC. Evaluation of screening instruments for depression and anxiety in breast cancer survivors. Breast Cancer Res Treat. 2010;122(2):573–8.CrossRefPubMed
47.
Leung CM, Ho S, Kan CS. Evaluation of the Chinese version of the hospital anxiety and depression scale: a cross-cultural perspective. Int J Psychosom. 1993;40:29–34.PubMed
48.
Huang H, Zhang J, Deng XM, Xu L. Application status of psychological rating scales for patients with cancer. Nurs J Chin PLA. 2006;23(5):59–62 (in Chinese).
49.
Zhang W, Wang W, Hong J, Chen Y. Research on critical value of Hospital Anxiety and Depression Scale in screening anxiety and depression of hospitalized cancer patients. Chin J Nurs. 2012;19:1–4 (in Chinese).
50.
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.PubMed
51.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.CrossRefPubMed
52.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.CrossRefPubMed
53.
Zhao H, Kanda K. Testing psychometric properties of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQC30). J Epidemiol. 2004;14(6):193–203.CrossRefPubMed
54.
Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs. 2007;11(1):6–15.CrossRefPubMed
55.
Biglia N, Bounous VE, Malabaila A, Palmisano D, Torta DM, D’Alonzo M, et al. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care (Engl). 2012;21(4):485–92.CrossRef
56.
Munir F, Kalawsky K, Lawrence C, Yarker J, Haslam C, Ahmed S. Cognitive intervention for breast cancer patients undergoing adjuvant chemotherapy: a needs analysis. Cancer Nurs. 2011;34(5):385–92.CrossRefPubMed
57.
Todd BL, Feuerstein EL, Feuerstein M. When breast cancer survivors report cognitive problems at work. Int J Psychiatry Med. 2011;42(3):279–94.CrossRefPubMed
58.
Chan RCK, Shum D, Toulopoulou T, Chen EYH. Assessment of executive functions: review of instruments and identification of critical issues. Arch Clin Neuropsychol. 2008;23(2):201–16.CrossRefPubMed
59.
Feuerstein M, Hansen JA, Calvio LC, Johnson L, Ronquillo JG. Work productivity in brain tumor survivors. J Occup Environ Med. 2007;49(7):803–11.CrossRefPubMed
60.
Lezak MD. Neuropsychological assessment. 3rd ed. New York: Oxford University Press; 1995.
61.
Feuerstein M, Todd BL, Moskowitz MC, Bruns GL, Stoler MR, Nassif T, et al. Work in cancer survivors: a model for practice and research. J Cancer Surviv. 2010;4(4):415–37.CrossRefPubMed
62.
Maunsell E, Drolet M, Brisson J, Brisson C, Mâsse B, Deschênes L. Work situation after breast cancer: results from a population-based study. J Natl Cancer Inst. 2004;96:1813–21.CrossRefPubMed
63.
Kennedy F, Haslam C, Munir F, Pryce J. Returning to work following cancer: a qualitative exploratory study into the experience of returning to work following cancer. Eur J Cancer Care. 2007;16:17–25.CrossRef
64.
65.
Gonzalez-Calvo J, Gonzalez VM, Lorig K. Cultural diversity issues in the development of valid and reliable measures of health status. Arthritis Care Res. 1997;10:448–56.CrossRefPubMed
Metadata
Title
Validation of the Chinese Version of the Cognitive Symptom Checklist-Work-21 in Breast Cancer Survivors
Authors
Andy S. K. Cheng
Yingchun Zeng
Michael Feuerstein
Publication date
01-12-2015
Publisher
Springer US
Published in
Journal of Occupational Rehabilitation / Issue 4/2015
Print ISSN: 1053-0487
Electronic ISSN: 1573-3688
DOI
https://doi.org/10.1007/s10926-015-9576-3

Other articles of this Issue 4/2015

Journal of Occupational Rehabilitation 4/2015 Go to the issue

OriginalPaper

Workstyle and Musculoskeletal Discomfort (MSD): Exploring the Influence of Work Culture in Malaysia

OriginalPaper

Psychosocial Working Environment and Risk of Adverse Cardiac Events in Patients Treated for Coronary Heart Disease

OriginalPaper

Occupational Therapy Practitioners with Occupational Musculoskeletal Injuries: Prevalence and Risk Factors

OriginalPaper

What Challenges Manual Workers’ Ability to Cope with Back Pain at Work, and What Influences Their Decision to Call in Sick?

OriginalPaper

My Well-Being in My Own Hands: Experiences of Beneficial Recovery During Burnout Rehabilitation

OriginalPaper

The Predictive Validity of the Return-to-Work Self-Efficacy Scale for Return-to-Work Outcomes in Claimants with Musculoskeletal Disorders